



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Bucindolol

Item No. 21070

CAS Registry No.: 71119-11-4
Formal Name: 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy]-benzonitrile

Synonyms: DL-Bucindolol, MJ13105-1

MF: C₂₂H₂₅N₃O₂

FW: 363.5


Purity: ≥98%

UV/Vis.: λ_{max}: 220, 283, 289 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

Bucindolol is supplied as a crystalline solid. A stock solution may be made by dissolving the bucindolol in the solvent of choice. Bucindolol is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of bucindolol in ethanol is approximately 500 µg/ml and approximately 20 and 30 mg/ml in DMSO and DMF, respectively.

Description

Bucindolol is a third-generation, non-selective β-adrenergic receptor blocker that acts on both β₁ and β₂ receptors.^{1,2} Formulations containing β-blockers, such as bucindolol, are used in managing chronic heart failure.³ Bucindolol is also a weak α₁-adrenoceptor antagonist, which may be linked to a mild vasodilator benefit.^{1,3}

References

1. Bristow, M.R., Roden, R.I., Lowes, B.D., *et al.* The role of third-generation beta-blocking agents in chronic heart failure. *Clin. Cardiol.* **21**(12 Suppl 1), I3-I13 (1998).
2. Maack, C., Cremers, B., Flesch, M., *et al.* Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. *Br. J. Pharmacol.* **130**(5), 1131-1139 (2000).
3. Smart, N.A., Kwok, N., Holland, D.J., *et al.* Bucindolol: A pharmacogenomic perspective on its use in chronic heart failure. *Clin. Med. Insights Cardiol.* **5**, 55-66 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/22/2017

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM